Risk factor
Good trading liquidity
Profitability factor
Very low or no dividends
About
SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell-cultured influenza vaccine, along with its pre-filled syringe version, Skycellflu 4-ga. The company also provides pneumococcal vaccines for both adults and children, Skyzoster for shingles, and Sky Baricella, designed to prevent chickenpox in pediatric patients. Beyond its existing portfolio, SK bioscience maintains an active research and development pipeline. Several candidates have completed Phase 2 clinical trials, including an oral rotavirus vaccine, a cervical cancer vaccine, and a low-cost pneumococcal vaccine. A distinct rotavirus vaccine is currently in Phase 3 trials in Africa, while a next-generation pneumococcal vaccine is undergoing Phase 2 trials in the United States. Other projects in development include a typhoid conjugate vaccine and a COVID-19 vaccine, which is progressing through Phase 1 and Phase 1/2 clinical studies. The company was established in 2018 and is headquartered in Seongnam-si, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of 302440.KS is 33042 and suggests 10.5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendatio